Page 1 of 1

Triomar, aka omega-3s - Norwegian study-RESULTS?

Posted: Thu May 22, 2008 6:22 am
by Longing4Cheese
Anyone know what's up with the study on "Triomar," which is I guess a pharmaceuticalized form of omega-3s?

It is listed as "COMPLETED" in its listing at ClinicalTrials.gov (identifier # NCT00360906), but in the study description it says

Estimated Enrollment: 100
Study Start Date: December 2004
Estimated Study Completion Date: July 2008

So, does this mean that the study was completed early (prior to estimated date of July '08), or maybe that the trial is over, but they will be releasing results in July?

I'd really like to read the results of the trial, but can't find them. Does anyone have a better understanding of this?

Thanks!

L4C

Posted: Thu May 22, 2008 11:46 am
by DIM
Ugeskr Laeger. 2001 Feb 19;163(8):1135-6.

Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients.

Nordvik I, Myhr KM, Nyland H, Bjerve KS.

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

OBJECTIVE: To investigate whether supplementation with fish oil given together with dietary advice and vitamin supplementation influenced the clinical outcome in newly diagnosed multiple sclerosis (MS) patients. MATERIAL AND METHODS: Sixteen consecutive, newly diagnosed patients with multiple sclerosis were recruited to an open intervention study. They were given dietary advice and supplemented with 0.9 g/day of long-chain marine fatty acids and vitamins. The patients were followed for 2 years with respect to dietary habits, blood parameters and neurological assessment including exacerbation rate. RESULTS: There was a significant reduction in the mean annual exacerbation rate and the mean Expanded Disability Status Scale (EDSS) as compared to pre-study values. The plasma total phospholipid n-3 fatty acids increased and n-6 fatty acids decreased significantly. CONCLUSIONS: The results suggest that fish oil supplementation given together with vitamins and dietary advice can improve clinical outcome in patients with newly diagnosed MS.

Publication Types:
Clinical Trial
Research Support, Non-U.S. Gov't

PMID: 10987373 [PubMed - indexed for MEDLINE]

Actually, it's a more recent study

Posted: Thu May 22, 2008 4:04 pm
by Longing4Cheese
Thanks, DIM ... but that was an older study, of "dietary advice" (was the advice to reduce sat fats?) and to take fish oil, reported in 2001.

I'm looking for the one started in 2004 and due to complete in July 2008, as per my original post. This one starts out with "Triomar" omega-3, then after an interval, all subjects take Rebif and continue with Triomar.

I'm skeptical of this study design (the om-3 naysayers may just claim any benefit was from Rebif, the pro-omega-3 crowd will say the benefit started with the omega-3s, is my fear), but interested to read it.

Does anyone know if / where this was published?

thanks,

Pas de Fromage

Posted: Thu May 22, 2008 9:45 pm
by DIM
According to the identifier # NCT00360906 these are the results clinicaltrials.gov gives me!

Still waiting for the report from the latest study

Posted: Thu May 22, 2008 10:31 pm
by Longing4Cheese
That's the publication that is listed/linked under "more information." It's the earlier study, published in 2000/2001, where they studied the effects of "dietary advice" and fish oil.

I guess they haven't published the results of the study that began in 2004 and finished in 2008, which is the omega-3 followed by Rebif-plus-omega-3 treatment regimen.

I wonder how long it takes usually, after a trial concludes, before a paper is published.

Re: Triomar, aka omega-3s - Norwegian study-RESULTS?

Posted: Fri May 23, 2008 6:56 pm
by CureOrBust
Longing4Cheese wrote:Anyone know what's up with the study on "Triomar," which is I guess a pharmaceuticalized form of omega-3s?
Its quiet interesting how they have chosen a commercially available product / dosage. It almost appears as if the manufacturer is sponsoring the trial in some way. I checked their web site, and I know its not an answer, but they have an email address post@collettpharma.no

Re: Actually, it's a more recent study

Posted: Fri May 23, 2008 7:03 pm
by CureOrBust
Longing4Cheese wrote:that was an older study, of "dietary advice" (was the advice to reduce sat fats?) and to take fish oil, reported in 2001.
This appear to be a presentation on the trial (translated) HERE
Reduce your intake of saturated fat in the diet and increase the amount of omega-3 fatty acids:

Spis fisk til middag 3 - 4 ganger i uken. Eat fish for dinner 3 - 4 times a week. Inkluder fet fisk - også som pålegg. Please include oily fish - including that order.
Velg magert kjøtt. Select magere meat. Kylling og kalkun anbefales også. Chicken and turkey are recommended as well.
Bruk skummet melk/ lettmelk og magre/ halvfete oster. Use foam milk / lettmelk and magre / halvfete cheeses.
Bruk olivenolje i matlagingen og reduser mengden av smør/ margarin på brødet. Use olive oil in cooking and reduce the amount of butter / margarine on bread.
Mengden antioksidanter økes ved å: The amount of antioxidants increased by:

Spise mye grønnsaker; rå eller lettkokte. Eat a lot of vegetables; raw or lettkokte.
Spise et par frukter hver dag. Eating a couple of fruit each day.
Bruk grove kornsorter Use grove kornsorter
Reduser inntaket av sukker, søtsaker, brus og kaker Reduce your intake of sugar, sweets, drinks and cakes

Reduser kaffe og svart te til et par kopper om dagen Reduce coffee and black tea to a couple of cups a day

Unngå matvarer som du reagerer negativt på Avoid foods that you react negatively on

Kosttilskudd (daglig - ved frokost): Dietary (daily - at the breakfast):

En skje Møllers tran (5 ml) A happen Mill tran (5 ml)
200 mg Ester-C (syrenøytral vitamin C) 200 mg Ester-C (syrenøytral vitamin C)
B-vitaminkompleks (Berthelsen Vegetamin) B-vitaminkompleks (Berthelsen Vegetamin)
I denne studien ble pasientene også bedt om å drikke så lite alkohol som mulig og å unngå røyking. In this study patients were also asked to drink alcohol as little as possible and to avoid smoking.

Translation of Dietary Advice

Posted: Fri May 23, 2008 10:21 pm
by Longing4Cheese
Wow, thanks, CureOrBust. That's some good internet sleuthing.

The dietary advice sure sounds Swanky to me.

I'm glad to know that I've already been doing all of this, and more, and that this trial found positive results.

I'd like to send this to Dr. Barbara Giesser of UCLA, who told me emphatically in February of 2008, and I quote, "There is not one iota of evidence that the Swank diet affects MS."

And this article was published in 2001.

Thanks again.

Longing4Cheese
but not missing it so badly when I see evidence that my "sacrifice" is productive =) :D

Giesser article

Posted: Sun May 25, 2008 7:13 am
by lyndacarol
Longing--you mentioned,
I'd like to send this to Dr. Barbara Giesser of UCLA, who told me emphatically in February of 2008, and I quote, "There is not one iota of evidence that the Swank diet affects MS."

And this article was published in 2001.
so I recognized her name immediately when I read her article, Exercise and Gait Retraining in Persons With Multiple Sclerosis in the Summer 2008 issue of MSQR (Multiple Sclerosis Quarterly Report), (To download publications free of charge, go to www.unitedspinal.org and click on publications at the top of the page.)

I found her feature story to be good with many citations, even to a recent Finnish study! Diet and exercise are effective, I believe, because of the connection to insulin, of course.
=============================
Here is some other information that I found interesting. It concerns how monoclonal antibodies are named.
In general, suffixes are used to identify a class of medicines; thus all monoclonal antibodies end with the suffix -mab. Different infixes (the syllables in the middle of the word), however, are used depending on the structure and function of the drug. The first syllable is a unique prefix developed by the pharmaceutical company. The next syllable describes the target that the antibody was developed to treat, for example "tu" is for tumor antibodies, "li" is for immune cell antibodies and so forth. The third infix is the source of the antibody, if it is mouse antibody "mo" is used, if it is humanized as described above, "zu" is used, and if it is chimeric "xi" is written. As we mentioned above, the last syllable is always the suffix "mab," standing for monoclonal antibody.